HOOKIPA Pharma Inc (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company that develops immunotherapies based on its proprietary arenavirus vector platform. The company generates cash primarily from upfront payments, milestone payments, and research funding under collaboration agreements with Gilead Sciences and Roche, rather than from product sales. Founded in 2011 and headquartered in Austria, HOOKIPA has no approved products as of the 10-K filed February 28, 2025. Its lead oncology asset, eseba-vec (HB-200), targets HPV16-positive cancers, and HB-700 targets mutated KRAS metastatic non-small cell lung cancer, with an IND cleared by the FDA in April 2024. Under its Gilead Collaboration Agreement signed in 2018, HOOKIPA is eligible for up to $185.0 million in further development and commercialization milestone payments plus tiered royalties on the Hepatitis B program. Since inception, operations have been funded through equity offerings, Austrian government grants and loans, and collaboration payments.

Revenue model

Collaboration revenue from upfront, initiation, and milestone payments under research and license agreements with Gilead Sciences and Roche. HOOKIPA is also eligible for tiered royalties on any future commercialized products. No product revenue has been generated as of the filing date.

Products and services

Arenavirus-based immunotherapy platform. Clinical and preclinical assets include: eseba-vec (HB-200) for HPV16-positive cancers; HB-700 for mutated KRAS metastatic non-small cell lung cancer (Phase 1/2 planned, first dosing targeted mid-2025 per 10-K filed 2025-02-28); a Hepatitis B product candidate in Phase 1 clinical trial conducted by Gilead (first participant dosed April 2023); and an HIV program candidate being developed by HOOKIPA through Phase 1b with Gilead funding.

Customers and end markets

Collaboration partners Gilead Sciences and Roche are the primary sources of revenue. End markets are oncology (HPV16-positive cancers, KRAS-mutant NSCLC) and infectious disease (chronic Hepatitis B, HIV). No commercial product customers exist as of the filing.

Value-chain role

Platform technology licensor and clinical-stage drug developer. HOOKIPA conducts preclinical and early-stage clinical development, then licenses development and commercialization rights to large pharma partners. Gilead is solely responsible for further development and commercialization of the Hepatitis B product candidate.

Geographic exposure

Incorporated and with research operations in Austria. Clinical and regulatory activities extend to the United States, including IND filings with the FDA. No commercial geographic revenue mix is disclosed.

Source: SEC 10-K, filed 2025-02-28

Industry: Pharmaceutical Preparations Peers: Assembly Biosciences Inc aTyr Pharma Inc Surrozen Inc Carisma Therapeutics Inc FINCH THERAPEUTICS GROUP, INC. MARIZYME, INC. NextCure Inc Onkure Therapeutics Inc Xilio Therapeutics Inc